India Pharmaceutical Sector Industry Analysis Report | Scrolls

by Karnivesh | 2026

Comprehensive Analysis od India's Pharmaceutical Sector.pdf

Download PDF • 1.18MB

India’s pharmaceutical industry stands at a defining crossroads. For decades, it has been the backbone of global affordable healthcare a sector built on scale, efficiency, and trust. Today, as healthcare systems worldwide face cost pressures, supply-chain realignments, and rising chronic disease burdens, India’s pharma sector is evolving from a volume-led generics powerhouse into a science-enabled global partner.

At its core, the industry is vast and deeply embedded in the economy. With over 3,000 companies, 10,000+ manufacturing facilities, and 650+ globally compliant plants, India has become the world’s largest supplier of generic medicines by volume. The sector contributes nearly 2% of India’s GDP, supports millions of direct and indirect jobs, and produces over 60,000 branded formulations across therapies ranging from anti-infectives to oncology.

Domestically, growth is being reshaped by a fundamental shift in India’s disease profile. As the country ages and lifestyles change, chronic diseases such as cardiac disorders, diabetes, and cancer now dominate demand. This has transformed the Indian pharmaceutical market from a low-value, acute-care driven system into a steady, value-led growth engine. The domestic market, valued at USD 55 billion in 2025, is projected to more than double to USD 120–130 billion by 2030, driven by chronic therapy expansion, deeper penetration into Tier-2 and Tier-3 cities, and institutional demand supported by government healthcare programs.

Globally, India’s influence is even more pronounced. Often referred to as the “pharmacy of the world,” India supplies one in five generic medicines used globally, including half of all generics consumed in the United States and 40% in the United Kingdom. In FY25, pharmaceutical exports reached USD 30.47 billion, growing at nearly 10% year-on-year, despite pricing pressure and regulatory scrutiny. This export engine is no longer reliant on a single geography Africa, Latin America, Southeast Asia, and the Middle East are emerging as fast-growing markets, reducing overdependence on the US.

Yet, this success has not come without strain. The very generics model that powered India’s rise now faces structural headwinds. Pricing erosion in the US, driven by buyer consolidation and policy-led reimbursement cuts, continues to compress margins. Heavy dependence on China for APIs exposes supply-chain vulnerabilities. Regulatory scrutiny has intensified, slowing approvals and raising compliance costs. At the same time, India’s R&D investment while improving still lags far behind global innovators.

Rather than resisting these pressures, the industry is reinventing itself.

A strategic pivot is underway—from simple generics to complex generics, biosimilars, specialty drugs, and contract development and manufacturing (CDMO). Indian companies are moving into high-barrier products such as injectables, inhalers, peptides, high-potency APIs, and biologics. Biosimilars are emerging as a major frontier, with India already commercializing complex monoclonal antibodies and targeting a USD 5–7 billion domestic opportunity by 2030.

The CDMO segment, in particular, marks a turning point. As global pharma companies diversify supply chains away from China, India is positioning itself as a trusted innovation and manufacturing partner, not just a low-cost supplier. CDMO platforms offer significantly higher margins, deeper client integration, and long-term revenue visibility—reshaping the industry’s earnings profile.

Policy support is reinforcing this transition. Government initiatives such as Production Linked Incentives are accelerating API self-reliance, reducing import dependence, and encouraging advanced manufacturing. Industry bodies are pushing for stronger R&D incentives, recognizing that innovation not scale alone will define the next phase of leadership.

Looking ahead to 2030, the picture is one of structural upshift. Exports are expected to reach USD 50–60 billion, with a fundamentally different mix less commoditized formulations, more specialty, biosimilars, and CDMO revenues. India is projected to move from 14th to among the top 5 pharmaceutical markets by value globally. Consolidation will strengthen leading players, margins are set to improve, and return on equity for industry leaders is expected to remain sustainably high.

In essence, India’s pharmaceutical story is no longer just about being the cheapest or the largest. It is about becoming indispensable to global healthcare systems, to innovation supply chains, and to the future of affordable medicine. If executed well, the journey from scale to science could transform India into a USD 450 billion pharma ecosystem by 2047, anchoring its role as both the world’s pharmacy and a global innovation hub.